A New In Vitro Diagnostic to predict response to Gemcitabine treatment in pancreatic cancer

Acobiom proposes a new In Vitro Diagnostic Multivariate Index Assay (IVDMIA), based on a new Blood RNA-biomarker signature, able to predict response to Gemcitabine (Gemzar) in Metastatic Pancreatic Cancer and to prognose a 14.9-month survival.

Acobiom discovered and patented a new innovative set of biomarkers identified through Omics and BIG DATA performed on blood samples that are correlated to a 14.9-month survival prognosis in Pancreatic Cancer patients treated by Gemcitabine.

This new In Vitro Diagnostic based on qRT-PCR technology, called GemciTest, is now available and can be ordered for « Research Use Only » (RUO).

The benefits of GemciTest on clinical and economical aspects are described on the following document: The Gemcitest flyer and in the following presentation: Gemcitest.

Moreover, regulatory queries are currently under review to obtain a CE mark, and a Pre-submission Request has been under review by FDA.

These results have recently been presented at a Cancer-Bio-Santé meeting (Toulouse, France, 8th of october 2015; see the GemciTest presentation) and at the « first Pancreatic Cancer Symposium » (Marseille, France, 28-30 october 2015, www.pcs-2015.com; see the GemciTest Poster).

These results have recently been presented at the following events :

> Research2Business Oncology Meeting 2016 (CLARA Canceropole, Lyon, Nov. 15, 2016), click here to download the presentation: R2B_2016_GemciTest
> French Society of Clinical Biology workshop on « Companion Tests in Clinical Biology » (Paris, Nov 17, 2016: ): click here to download the presentation: SFBC_2016_GemciTest
> 12th meeting of the Grand Sud Ouest Canceropole (La Grande Motte, France, Nov. 23-25, 2016), click here to download the presentation: GSO_2016_GemciTest

 

If you need more information, please contact our business development department

(T: +33(0)467 419 748, Email: info@acobiom.com).